The DCK gene, known for its increased expression in breast cancers with poor prognosis [88], is associated with the action of Decitabine, an FDA-approved drug for certain blood cancers [106], which has also been shown to significantly inhibit the growth of triple-negative breast cancer [107]. The gene discussed is DCK; the disease is triple-negative breast carcinoma.